Natera, Inc. (NASDAQ:NTRA - Get Free Report) CFO Michael Burkes Brophy sold 1,378 shares of the stock in a transaction that occurred on Tuesday, April 2nd. The stock was sold at an average price of $92.62, for a total value of $127,630.36. Following the transaction, the chief financial officer now directly owns 70,646 shares of the company's stock, valued at $6,543,232.52. The sale was disclosed in a filing with the SEC, which is available at this link.
Michael Burkes Brophy also recently made the following trade(s):
- On Thursday, March 28th, Michael Burkes Brophy sold 914 shares of Natera stock. The stock was sold at an average price of $90.42, for a total value of $82,643.88.
- On Tuesday, March 5th, Michael Burkes Brophy sold 2,826 shares of Natera stock. The stock was sold at an average price of $88.36, for a total transaction of $249,705.36.
- On Tuesday, February 6th, Michael Burkes Brophy sold 34,029 shares of Natera stock. The shares were sold at an average price of $70.03, for a total transaction of $2,383,050.87.
- On Thursday, February 1st, Michael Burkes Brophy sold 22,281 shares of Natera stock. The stock was sold at an average price of $67.73, for a total transaction of $1,509,092.13.
- On Monday, January 29th, Michael Burkes Brophy sold 3,235 shares of Natera stock. The shares were sold at an average price of $65.09, for a total transaction of $210,566.15.
- On Tuesday, January 23rd, Michael Burkes Brophy sold 2,202 shares of Natera stock. The stock was sold at an average price of $65.86, for a total value of $145,023.72.
Natera Trading Down 0.3 %
The Best AI Stock to Own in the World Today is Trading for Just $25
From Banyan Hill Publishing | Ad
“Titan of Tech” Bets Big on Tiny AI Company
He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal…
But our research shows his latest investment could be his most successful venture yet.
See how you can invest alongside him
Shares of Natera stock opened at $92.36 on Friday. Natera, Inc. has a fifty-two week low of $36.90 and a fifty-two week high of $96.80. The business's fifty day moving average is $80.59 and its two-hundred day moving average is $62.33. The company has a quick ratio of 3.96, a current ratio of 4.10 and a debt-to-equity ratio of 0.37. The firm has a market cap of $11.15 billion, a PE ratio of -24.37 and a beta of 1.37.
Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings data on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.09. Natera had a negative net margin of 40.16% and a negative return on equity of 62.19%. The business had revenue of $311.11 million for the quarter, compared to analyst estimates of $300.38 million. Analysts anticipate that Natera, Inc. will post -2.35 earnings per share for the current year.
Hedge Funds Weigh In On Natera
A number of hedge funds have recently made changes to their positions in the stock. Norges Bank acquired a new position in shares of Natera in the 4th quarter valued at about $111,690,000. Alliancebernstein L.P. increased its position in shares of Natera by 2,280.5% in the fourth quarter. Alliancebernstein L.P. now owns 1,202,382 shares of the medical research company's stock worth $48,300,000 after acquiring an additional 1,151,873 shares in the last quarter. State Street Corp raised its stake in shares of Natera by 54.8% in the 1st quarter. State Street Corp now owns 2,832,266 shares of the medical research company's stock valued at $115,217,000 after acquiring an additional 1,002,444 shares during the period. American Century Companies Inc. raised its stake in shares of Natera by 115.7% in the 3rd quarter. American Century Companies Inc. now owns 1,654,303 shares of the medical research company's stock valued at $73,203,000 after acquiring an additional 887,409 shares during the period. Finally, Invesco Ltd. lifted its holdings in shares of Natera by 52.0% during the 3rd quarter. Invesco Ltd. now owns 2,529,496 shares of the medical research company's stock valued at $111,930,000 after acquiring an additional 865,404 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company's stock.
Analyst Ratings Changes
NTRA has been the subject of several research reports. Stephens reaffirmed an "overweight" rating and set a $78.00 price objective on shares of Natera in a report on Tuesday, January 30th. Wolfe Research initiated coverage on shares of Natera in a research report on Wednesday, December 13th. They issued an "outperform" rating and a $70.00 price objective on the stock. Canaccord Genuity Group raised their target price on shares of Natera from $87.00 to $100.00 and gave the company a "buy" rating in a report on Thursday, February 29th. Raymond James downgraded shares of Natera from a "strong-buy" rating to an "outperform" rating and upped their price target for the company from $68.00 to $85.00 in a report on Tuesday, February 20th. Finally, BTIG Research raised their price objective on shares of Natera from $75.00 to $85.00 and gave the stock a "buy" rating in a research note on Friday, December 29th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and twelve have given a buy rating to the stock. Based on data from MarketBeat, Natera has an average rating of "Moderate Buy" and an average price target of $78.36.
Get Our Latest Analysis on NTRA
About Natera
(
Get Free Report)
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
